Recorded Q4’24 consolidated revenue of KRW 1.26 trillion Recorded FY’24 consolidated revenue of KRW 4.55 trillion Poised for further growth with expanded capacity and new service offerings INCHEON, South Korea, Jan. 22, 2025 /PRNewswire/ — Samsung Biologics (KRX: 207940.KS), a global…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.